Market Quotes Powered By Forexpros, the Forex, Futures, and Stock Markets Portal.
Astra Zeneca making multi billion business in the USA
Monday, 23 April 2012
AstraZeneca acquires US-based Ardea Biosciences for $32 per share,
making the purchase price amounts to about 1.26 billion U.S. dollars
including existing cash.
Astra Zeneca, with CEO David Brennan, acquires US-based Ardea
Biosciences for $ 32 per share, making the purchase price amounts to
approximately 1.26 billion dollars - equivalent to Skr8.4 billion -
including existing cash according to a press release.
Ardea is a biotechnology company in San Diego that focuses on
developing small molecule drugs. Ardeas clinically most advanced
product candidate, lesinurad (formerly known as RDEA594), is currently
in Phase 3 as a potential treatment for chronic management of
hyperuricemia in patients with gout.
The purchase price of approximately 1.26 billion dollars, including
existing cash, representing a premium of 50 percent based on the volume
weighted average price for one month and 54 percent based on the
closing price on Friday, 20 April 2012.
By Scancomark.se Team
What do you think about this
article or us? Please leave a comment. Thank you!